Trends in Cancer

Article	Citations
Subscription & copyright page	317
FBXW10: a male-biased E3 ligase in liver cancer	193
Engineering growth factor ligands and receptors for therapeutic innovation	183
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	180
Spliced to kill: RNA mis-splicing derived cancer neoantigens	171
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	165
Platelets: tailoring metastasis treatment	153
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	150
Revumenib: a new era in acute leukemia treatment	138
Tumor-resident microbes: the new kids on the microenvironment block	137
Advisory Board and Contents	136
Subscription & copyright page	135
Navigating life as an early career researcher	128
Subscription and copyright page	128
Onco-condensates: formation, multi-component organization, and biological functions	127
Engine shutdown: migrastatic strategies and prevention of metastases	124
Accessing the vasculature in cancer: revising an old hallmark	119
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	116
Radiotherapy and immunotherapy: open questions and future strategies	115
Leveraging circulating microbial DNA for early cancer detection	113
Subscription & copyright page	104
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	90
GOT2 consider the tumor microenvironment	81
Advisory Board and Contents	80
Chromatin as an old and new anticancer target	75

Oncogenic competence: balancing mutations, cellular state, and microenvironment	75
Tumor immunology CRISPR screening: present, past, and future	74
Gut microbiota – a double-edged sword in cancer immunotherapy	73
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	73
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	73
Recent developments in myeloid immune modulation in cancer therapy	70
Benefits and opportunities of the transgenic Oncopig cancer model	68
Chromosomal instability and aneuploidy as causes of cancer drug resistance	67
Regulation of metastatic organotropism	65
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	64
Diet, nutrient supply, and tumor immune responses	63
Pannexin biology and emerging linkages to cancer	63
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	63
Crosstalk of T cells within the ovarian cancer microenvironment	62
Cell death, therapeutics, and the immune response in cancer	60
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	60
Subscription & copyright page	57
Subscription & copyright page	56
Advisory Board and Contents	56
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	55
Cancer catecholamine conundrum	55
Advisory Board and Contents	55
Genetic immune escape in cancer: timing and implications for treatment	55
Palmitate paves the way to lung metastasis	52
Scaling data toward pan-cancer foundation models	50
Advisory Board and Contents	49
Subscription & copyright page	48
β-Galactosylceramidase in cancer: friend or foe?	48
Insights on ErbB glycosylation – contributions to precision oncology	47
Inflammation: the incubator of the tumor microenvironment	46
Advisory Board and Contents	45
Clinical and translational relevance of intratumor heterogeneity	45
Advisory Board and Contents	45
The emerging field of oncolytic virus-based cancer immunotherapy	45
Advisory Board and Contents	44
Subscription & copyright page	43
Advisory Board and Contents	43
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	43
Redefining precision cancer prevention to promote health equity	43
Subscription and copyright page	43
Modeling metastasis in mice: a closer look	42
Stress granules and hormetic adaptation of cancer	42
Advancing cancer precision surgery with the tumor coagulome	41
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	41
Molecular and clinical insights into early-onset endometrial cancer	40
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	40
B7-H3: a robust target for immunotherapy in prostate cancer	40
RHOA takes the RHOad less traveled to cancer	39
Prospects for understanding and exploiting the consequences of hyperactivation lethality	39
Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges	39

Updating cancer research with patient-focused networks	38
Circulating cell-free DNA-based multi-cancer early detection	38
Emerging mechanisms of telomerase reactivation in cancer	38
Advisory Board and Contents	37
Advisory Board and Contents	37
Subscription & copyright page	36
Targeting TIM-3 to halt lung precancer progression	36
Advisory Board and Contents	36
Cross-dressing of dendritic cells strengthens antitumor immunity	35
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	35
A tipping point in cancer epidemiology: embracing a life course exposomic framework	35
Beyond safety: suicide systems in cell-based cancer therapies	35
A macrophage-neutrophil program drives mammary carcinogenesis	35
Immune response and inflammation in cancer health disparities	35
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	34
Dissecting liver tumor heterogeneity to improve health equity	34
Advisory Board and Contents	34
Leveraging space innovations for cancer breakthroughs on Earth	34
Neoantigen-directed therapeutics in the clinic: where are we?	33
Functional heterogeneity of fibroblasts in primary tumors and metastases	33
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises	33
Time-of-day dependency of adoptive cell therapies	32
Advisory Board and Contents	31
Subscription & copyright page	31
Cancer cell adaptability: turning ribonucleoprotein granules into targets	31
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Engineered bacterial therapeutics for detecting and treating CRC	30
Advisory Board and Contents	30
Space in cancer biology: its role and implications	29
Clonal evolution and hierarchy in myeloid malignancies	29
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	28
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	28
Ferroptosis vulnerability in FLT3-mutant leukemia	28
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	28
Epigenetic basis and targeting of cancer metastasis	28
Advisory Board and Contents	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
Addressing the genetic/nongenetic duality in cancer with systems biology	27
Subscription & copyright page	27
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	26
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	26
Next-generation immunotherapies for brain metastatic cancers	26
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	26
NETscape or NEThance: tailoring anti-cancer therapy	25
Genitourinary cancer neoadjuvant therapies: current and future approaches	25
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	25
The development of therapy related myeloid neoplasms in childhood cancer survivors	25
Lifileucel: the first cellular therapy approved for solid tumours	24
Immunomodulation by endothelial cells: prospects for cancer therapy	24
Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic	24
Next-generation cancer vaccines and emerging immunotherapy combinations	24
Subscription & copyright page	23
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	23
Deciphering the roles of ABCB5 in normal and cancer cells	23
Future perspectives on engineered T cells for cancer	22
The extracellular matrix in cancer: from understanding to targeting	22
Embracing diversity: macrophage complexity in cancer	22
Successfully targeting the cancer system with metronomics for medulloblastoma	22
Persisting cancer cells are different from bacterial persisters	22
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	21
Tissue architecture in tumor initiation and progression	21
How cancer cells make and respond to interferon-I	21
Defining obesity in the context of cancer: thinking beyond body mass index	20
TET2, tumor control, and CAR T cell hyperproliferation	20
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity	20
Acetylation: a new target for protein degradation in cancer	20
Subscription & copyright page	20
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy	20
Enhancing dendritic cells by inhibiting BCL2	20
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	20
Think zebras: challenges and opportunities for treating rare cancers	20
The clinical landscape of CAR-engineered unconventional T cells	19
Emerging and extensive clonal evolution in the pancreas	19
Poised epigenetic states dictate metastatic fitness	19
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	19
New York’s Polyethnic-1000: a regional initiative to understand how diverse ancestries influence the risk, progression, and treatment of cancers	19
Tackling PARP inhibitor resistance	18
Revisiting the HIF switch in the tumor and its immune microenvironment	18
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	18
Nanomedicine-based strategies to target and modulate the tumor microenvironment	18

Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	17
Extracellular vesicle lipids in cancer immunoevasion	17
Every patient	17
Hypoxia orchestrates the lymphovascular–immune ensemble in cancer	17
Advisory Board and Contents	17
Subscription & copyright page	17
Targeting ferroptosis in pancreatic cancer: a double-edged sword	17
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	17
Advisory Board and Contents	17
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence	16
Exploiting T cell signaling to optimize engineered T cell therapies	16
The tumor-draining lymph node as a reservoir for systemic immune surveillance	16
Intracranial CAR-T cell delivery in glioblastoma patients	16
Tissue mechanics in tumor heterogeneity and aggression	16
Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy	15
A novel transcriptomic-based classifier for senescent cancer cells	15
Dynamic immune signatures as biomarkers for irAEs	15
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	15
Limited dsRNA editing impedes leukemia stem cells	15
Interferon epsilon and ovarian cancer	15
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells	15
Current landscape of CD3 bispecific antibodies in hematologic malignancies	15
Subscription & copyright page	15
Hypertranscription and replication stress in cancer	15
Tackling the next decade of cancer research	15
Wargaming cancer: a strategy for future precision oncology?	14
Targeting phagocytosis to enhance antitumor immunity	14
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy	14
Advisory Board and Contents	14
Lifestyle and host determinants of antitumor immunity and cancer health disparities	14
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency	14
Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma	14
Reductive stress in cancer: coming out of the shadows	13
Adaptive inhibition of CGAS signaling by TREX1	13
mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression	13
KRAS inhibitors: resistance drivers and combinatorial strategies	13
Spatial promoter–enhancer hubs in cancer: organization, regulation, and function	13
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	12
State-matched organoid models to fight pancreatic cancer	12
Modeling tumor plasticity in organoid models of human cancer	12
The peritumor microenvironment: physics and immunity	12
On the path to equity in cancer research and care	12
Subscription & copyright page	12
Impact of tissue-agnostic approvals on management of primary brain tumors	12
Advances in targeting RNA modifications for anticancer therapy	12
Ancestry-defined molecular taxonomy of prostate cancer	12
Subscription & copyright page	12
Label-free optical imaging for brain cancer assessment	12
Advisory Board and Contents	11
Necroptosis and tumor progression	11
Myeloid cell path to malignancy: insights into liver cancer	11
Metabolic landscape of disseminated cancer dormancy	11
Subscription & copyright page	11
Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy	11
Advisory Board and Contents	11
Advisory Board and Contents	11
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	11
Into the era of mycobiome-driven cancer research	11
Subscription & copyright page	11
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma	11
Immune organoids: from tumor modeling to precision oncology	11
Emerging roles of nucleotide metabolism in cancer	10
Subscription and copyright page	10
Epigenetic control of immunoevasion in cancer stem cells	10
Advisory Board and Contents	10
Drug independence and the curability of cancer by combination chemotherapy	10
Immunometabolism of CD8+ T cell differentiation in cancer	10
Neuro-immune interactions and immuno-oncology	10
Targeting vulnerabilities of aneuploid cells for cancer therapy	9
Advisory Board and Contents	9
Optimizing the future: how mathematical models inform treatment schedules for cancer	9
Diversity upon diversity: linking DNA double-strand break repair to blood cancer health disparities	9
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy	9
An epigenetic signature in CD19-CAR T cells predicts clinical outcome	9
EZHIP’s role in diffuse midline glioma: echoes of oncohistones?	9
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?	9
Cancer fitness genes: emerging therapeutic targets for metastasis	9
Immune cells in residual disease and recurrence	9
Trends in cancer imaging	8
CD4+ T cells in antitumor immunity	8
Targeting cancer stem cells in multiple myeloma	8
Immune mechanisms of toxicity from checkpoint inhibitors	8
Plastic persisters: revival stem cells in colorectal cancer	8
The future of cancer research: invest now	8
Low tumor mutational burden and immunotherapy in gliomas	8
Neuronal and tumourigenic boundaries of glioblastoma plasticity	8
Targeting phagocytosis to enhance antitumor immunity	7
Advisory Board and Contents	7
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity	7
Engineering stem cells for cancer immunotherapy	7
Challenges in glioblastoma research: focus on the tumor microenvironment	7
Subscription &copyright page	7
Generation of tumor neoantigens by RNA splicing perturbation	7
Subscription & copyright page	7
Modulating β-catenin homeostasis for cancer therapy	7